TRMT11 and non-small cell lung carcinoma: Our results showed that TRMT11-GRIK2 is present in all seven types of human malignancies (Table 1, Fig. 2 and Supplemental Figs 1–6)), including breast cancer (41/60, 68.33%), colon cancer (25/60, 41.7%), esophageal adenocarcinoma (9/34, 26.5%), hepatocellular carcinoma (9/70, 12.9%), ovarian adenocarcinoma (28/61, 45.9%), glioblastoma multiforme (26/150, 17.3%) and non-small cell lung cancer (39/141, 27.7%).